{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:58:55Z","timestamp":1790024335467,"version":"4.0.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.clinthera.2017.10.010","type":"journal-article","created":{"date-parts":[[2017,11,23]],"date-time":"2017-11-23T22:21:05Z","timestamp":1511475665000},"page":"2146-2157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review"],"prefix":"10.1016","volume":"39","author":[{"given":"Gurleen","family":"Pasricha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parikshit","family":"Padhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Daboul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dulabh K.","family":"Monga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.10.010_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35\u2009825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/jca.4502","article-title":"Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: a Seer analysis","volume":"3","author":"Tsikitis","year":"2012","journal-title":"J Cancer"},{"issue":"Suppl. 7","key":"10.1016\/j.clinthera.2017.10.010_bib3","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mdq290","article-title":"Gastrointestinal neuroendocrine tumors","volume":"21","author":"Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.dld.2015.12.013","article-title":"Patient-reported outcomes with lanreotide Autogel\/depot for carcinoid syndrome: an international observational study","volume":"48","author":"Ruszniewskia","year":"2016","journal-title":"Dig Liver Dis"},{"issue":"11","key":"10.1016\/j.clinthera.2017.10.010_bib5","first-page":"2201","article-title":"[The life of S. Oberndorfer: the proposer of the term \"carcinoid\"--the outcome of a seed in the past 100 years]","volume":"67","author":"Soga","year":"2009","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.clinthera.2017.10.010_bib6","series-title":"WHO Classification of Tumours of the Digestive System","year":"2010"},{"key":"10.1016\/j.clinthera.2017.10.010_bib7","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/PAS.0000000000000662","article-title":"A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas","volume":"40","author":"Tang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib9","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/00365528809090760","article-title":"Clinical presentation and prognosis of gastrointestinal carcinoid tumours","volume":"23","author":"Sj\u00f6blom","year":"1988","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib10","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.3748\/wjg.14.5377","article-title":"Neuroendocrine tumors of the gastro-entero-pancreatic system","volume":"14","author":"Massironi","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib11","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJM199206253262601","article-title":"Localization of pancreatic endocrine tumors by endoscopic ultrasonography","volume":"326","author":"R\u00f6sch","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.10.010_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.gie.2009.12.006","article-title":"EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience","volume":"71","author":"Pais","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.clinthera.2017.10.010_bib13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2015.64.0987","article-title":"Prospective study of 68Ga-DOTATATE positron emission tomography\/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites","volume":"34","author":"Sadowski","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/MPA.0b013e31828e34a4","article-title":"The NANETS consensus guideline for the management and treatment of neuroendocrine tumors","volume":"42","author":"Kunz","year":"2013","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.clinthera.2017.10.010_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.sla.0000167862.52309.7d","article-title":"Gastric carcinoids: biological behavior and prognosis after differentiated treatment in relation type","volume":"242","author":"Borch","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.clinthera.2017.10.010_bib16","doi-asserted-by":"crossref","first-page":"8687","DOI":"10.3748\/wjg.v19.i46.8687","article-title":"Metastatic type 1 gastric carcinoid: a real threat or just a myth?","volume":"19","author":"Grozinsky-Glasberg","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib17","first-page":"191","article-title":"Gastric carcinoid tumors","volume":"8","author":"Wardlaw","year":"2008","journal-title":"Ochsner J"},{"key":"10.1016\/j.clinthera.2017.10.010_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"issue":"6","key":"10.1016\/j.clinthera.2017.10.010_bib19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1241::AID-CNCR5>3.0.CO;2-4","article-title":"Carcinoid tumors of the ampulla of Vater: a comparison with duodenal carcinoid tumors","volume":"85","author":"Makhlouf","year":"1999","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clinthera.2017.10.010_bib20","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archsurg.2009.80","article-title":"Neuroendocrine tumors of the ampulla of Vater: biological behavior and surgical management","volume":"144","author":"Carter","year":"2009","journal-title":"Arch Surg"},{"key":"10.1016\/j.clinthera.2017.10.010_bib21","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/1097-0142(19920515)69:10<2400::AID-CNCR2820691003>3.0.CO;2-Z","article-title":"Incidence and mortality of carcinoids of the colon: data from the Connecticut Tumor Registry","volume":"69","author":"Ballantyne","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2017.10.010_bib22","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000335594","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms","volume":"95","author":"Caplin","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clinthera.2017.10.010_bib23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0002-9610(06)80019-X","article-title":"Treatment of rectal carcinoid tumors","volume":"160","author":"Shirozu","year":"1990","journal-title":"Am J Surg"},{"key":"10.1016\/j.clinthera.2017.10.010_bib24","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1245\/s10434-006-9311-6","article-title":"Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment","volume":"14","author":"Fahy","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archsurg.143.5.471","article-title":"Rectal carcinoid tumors: review of results after endoscopic and surgical therapy","volume":"143","author":"Kwaan","year":"2008","journal-title":"Arch Surg"},{"key":"10.1016\/j.clinthera.2017.10.010_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.gie.2010.01.040","article-title":"Endoscopic submucosal dissection for treatment of rectal carcinoid tumors","volume":"72","author":"Hye-Won","year":"2010","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.clinthera.2017.10.010_bib27","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.clinthera.2017.10.010_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1067\/msy.2001.110426","article-title":"Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years","volume":"129","author":"Nave","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.clinthera.2017.10.010_bib30","series-title":"Surgical treatment: evidence\u2013based and problem oriented Munich","year":"2001"},{"key":"10.1016\/j.clinthera.2017.10.010_bib31","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1245\/ASO.2003.03.026","article-title":"Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients","volume":"10","author":"Pawlik","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib32","doi-asserted-by":"crossref","unstructured":"Kennedy A, Bester L, Salem R et al. Role of intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17:29.","DOI":"10.1111\/hpb.12326"},{"key":"10.1016\/j.clinthera.2017.10.010_bib33","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1007\/s00268-002-6629-5","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases","volume":"26","author":"Berber","year":"2002","journal-title":"World J Surg"},{"key":"10.1016\/j.clinthera.2017.10.010_bib34","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.surg.2007.01.036","article-title":"Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10 year experience evaluating predictors of survival","volume":"142","author":"Mazzaglia","year":"2007","journal-title":"Surgery"},{"key":"10.1016\/j.clinthera.2017.10.010_bib35","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s11605-008-0640-6","article-title":"Hepatic neuroendocrine metastasis: chemo or bland embolization?","volume":"12","author":"Pitt","year":"2008","journal-title":"J Gastrointest Surg"},{"issue":"suppl","key":"10.1016\/j.clinthera.2017.10.010_bib36","article-title":"Survival following Y90 radioembolization for neuroendocrine tumor liver metastases: a retrospective, single-center analysis","volume":"32","author":"Gruener","year":"2014","journal-title":"L Clin. Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib37","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-011-0248-1","article-title":"Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres","volume":"35","author":"Paprottka","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(03)00235-9","article-title":"Somatostatin receptors","volume":"1616","author":"Moller","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.clinthera.2017.10.010_bib39","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropathic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.10.010_bib40","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib41","first-page":"81","article-title":"Above-label doses of octreotide\u2013LAR in patients with metastatic small intestinal carcinoid tumors","volume":"6","author":"Strosberg","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.clinthera.2017.10.010_bib42","first-page":"4127","article-title":"High dose octreotide acetate for management of gastroenteropathic neuroendocrine tumors","volume":"29","author":"Chadha","year":"2009","journal-title":"Anticancer Res"},{"issue":"102","key":"10.1016\/j.clinthera.2017.10.010_bib43","doi-asserted-by":"crossref","first-page":"8573","DOI":"10.1073\/pnas.0503224102","article-title":"The NF1 tumor suppressor critically regulates TSC2 and mTOR","volume":"14","author":"Johannessen","year":"2005","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"10.1016\/j.clinthera.2017.10.010_bib44","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.clinthera.2017.10.010_bib45","doi-asserted-by":"crossref","first-page":"6162","DOI":"10.1002\/cncr.27675","article-title":"Phase 2 study of everolimus monotherapy in patients with non-functioning neuroendocrine tumors or pheochromocytomas\/paragangliomas","volume":"118","author":"Oh","year":"2012","journal-title":"Cancer"},{"issue":"9808","key":"10.1016\/j.clinthera.2017.10.010_bib46","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeating for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomized placebo-controlled phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.10.010_bib47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"issue":"10022","key":"10.1016\/j.clinthera.2017.10.010_bib48","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomized, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.10.010_bib49","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.10.010_bib50","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib51","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2017.10.010_bib52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.10.010_bib53","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(15)70136-1","article-title":"Pazopanib and depot octreotide in advanced, well differentiated neuroendocrine tumors: a multicenter, single-group, phase 2 study","volume":"16","author":"Phan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib54","first-page":"1695","article-title":"Phase III prospective randomized comparison of depot octreotide plus interferon alpha-2b versus depot octreotide plus bevacizumab in advanced, poor prognosis carcinoid patients","volume":"35","author":"Yao","year":"2017","journal-title":"SWOG S0518: J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clinthera.2017.10.010_bib55","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2017.10.010_bib56","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000439086","article-title":"Streptozocin and 5-fluorouracil for the treatment of pancreatic neuroendocrine tumors: efficacy, prognostic factors and toxicity","volume":"103","author":"Clewemar","year":"2016","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.clinthera.2017.10.010_bib57","doi-asserted-by":"crossref","unstructured":"Krug S, Boch M, Daniel H et al. Streptozocin-based chemotherapy in patients with advanced neuroendocrine neoplasms-predictive and prognostic markers for treatment stratification. PLoS One 10: e0143822.","DOI":"10.1371\/journal.pone.0143822"},{"issue":"22","key":"10.1016\/j.clinthera.2017.10.010_bib58","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib59","doi-asserted-by":"crossref","unstructured":"Fine RL, Gulati AP, Tsushima D et al. Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol. 2014 (suppl 3); 32: Abstract 179.","DOI":"10.1200\/jco.2014.32.3_suppl.179"},{"key":"10.1016\/j.clinthera.2017.10.010_bib60","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1634\/theoncologist.2015-0470","article-title":"The role of capecitabine\/temozolomide in metastatic neuroendocrine tumors","volume":"21","author":"Ramirez","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clinthera.2017.10.010_bib61","doi-asserted-by":"crossref","unstructured":"Chaves A, Garcia A, Ribeiro J et al. Capecitabine and temozolomide (CAPTEM) in patients with advanced neuroendocrine tumors: the experience of a Portuguese cancer center. Cancer Chemother Pharmacol. 2013;71:663\u2013670.","DOI":"10.1007\/s00280-012-2055-z"},{"key":"10.1016\/j.clinthera.2017.10.010_bib62","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1159\/000444087","article-title":"Oxaliplatin-Based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors","volume":"103","author":"Spada","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"15 suppl","key":"10.1016\/j.clinthera.2017.10.010_bib63","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1200\/jco.2008.26.15_suppl.15545","article-title":"Phase II trial of FOLFOX plus Bevacizumab in advanced progressive neuroendocrine tumors","volume":"26","author":"Venook","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clinthera.2017.10.010_bib64","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor mediated radionuclide therapy with 90Y - DOTATOC in association with amino acid infusion:a phase 1 study","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"10.1016\/j.clinthera.2017.10.010_bib65","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, Survival, and Long-term toxicity after therapy with radiolabeled somatostatin analogue (90Y-DOTA)-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Inhof","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib66","first-page":"663","article-title":"Satya Prakash MVS Perioperative management of carcinoid syndrome\u2014an anaesthesiologist's perspective","volume":"7","year":"2016","journal-title":"J Anesth Clin Res"},{"key":"10.1016\/j.clinthera.2017.10.010_bib67","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"14","key":"10.1016\/j.clinthera.2017.10.010_bib68","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2017.10.010_bib69","doi-asserted-by":"crossref","unstructured":"Kulke MH, Horsch D, Caplin ME. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 35:14-23.","DOI":"10.1200\/JCO.2016.69.2780"},{"key":"10.1016\/j.clinthera.2017.10.010_bib70","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1159\/000440621","article-title":"Niacin (Vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor","volume":"103","author":"Bouma","year":"2016","journal-title":"Neuroendocrinology"},{"issue":"12","key":"10.1016\/j.clinthera.2017.10.010_bib71","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.clon.2015.06.016","article-title":"Variation in cardiac screening and management of carcinoid heart disease in the UK and Republic of Ireland","volume":"27","author":"Dobson","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"20","key":"10.1016\/j.clinthera.2017.10.010_bib72","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","article-title":"Early and late outcomes of surgical treatment in carcinoid heart disease","volume":"66","author":"Connolly","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817310160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T18:35:03Z","timestamp":1570386903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817310160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":72,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0149291817310160"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.10.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}